Search Results - "Hock, Hanno R."

A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation by Fathi, Amir T., Li, Shuli, Soiffer, Robert J., Levis, Mark, Mims, Alice S., Devine, Steven M, Defilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Spitzer, Thomas R., Frigault, Matthew J, Dey, Bimalangshu R., Amrein, Philip C., Hobbs, Gabriela S., Brunner, Andrew M., Hock, Hanno R., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Brown, Jami L., Del Rio, Candice J., Vanderklish, Julie E., Danielson, Colleen, Saylor, Meredith L., Hunnewell, Chrisa L., Perry, Lindsey H., Wahl, Jonathan L., Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin

“…Characterization of molecular alterations in acute myeloid leukemia (AML) has led to development of targeted therapies, including FLT3 and IDH1/2 inhibitors…”
Get full text

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial by Brunner, Andrew M, Blonquist, Traci M, DeAngelo, Daniel J, McMasters, Malgorzata, Fell, Geoffrey, Hermance, Nicole M, Winer, Eric S, Lindsley, R Coleman, Hobbs, Gabriela S, Amrein, Philip C, Hock, Hanno R, Steensma, David P, Garcia, Jacqueline S, Luskin, Marlise R, Stone, Richard M, Ballen, Karen K, Rosenblatt, Jacalyn, Avigan, David, Nahas, Myrna R, Mendez, Lourdes M, McAfee, Steven L, Moran, Jenna A, Bergeron, Meghan, Foster, Julia, Bertoli, Christina, Manning, Amity L, McGregor, Kristin L, Fishman, Kaitlyn M, Kuo, Frank C, Baltay, Michele T, Macrae, Molly, Burke, Meghan, Behnan, Tanya, Wey, Margaret C, Som, Tina T, Ramos, Aura Y, Rae, Jessica, Lombardi Story, Jennifer, Nelson, Nicole, Logan, Emma, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A, Fathi, Amir T

“…Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore…”
Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey G, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven, Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Get full text

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia by Fathi, Amir T., Fell, Geoffrey G, El-Jawahri, Areej, Perl, Alexander E., Jonas, Brian A., Dias, Ajoy L., Mims, Alice S., Borate, Uma, Ragon, Brittany Knick, Grunwald, Michael R., Peters, Mary Linton B., Graubert, Timothy A., Amrein, Philip C., Hock, Hanno R., Brunner, Andrew M., Hobbs, Gabriela S., Narayan, Rupa, Neuberg, Donna S., Aldoss, Ibrahim

Get full text

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML) by Fathi, Amir T., Perl, Alexander E., Levis, Mark, Smith, Catherine C., Brunner, Andrew M., Takahashi, Koichi, Amrein, Philip C., Hock, Hanno R., Hobbs, Gabriela S., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Daver, Naval, DiNardo, Courtney D.

“…Characterization of pathogenic alterations in acute myeloid leukemia (AML) has led to development of promising targeted therapies, including FLT3 (FLT3i) and…”
Get full text

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Stevenson, Kristen E., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Graubert, Timothy A., Neuberg, Donna S., Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

“…Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged…”
Get full text

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies by How, Chi-Joan, Ren, Siyang, Lombardi Story, Jennifer, Bergeron, Meghan, Foster, Julia E., Amrein, Philip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno R., Moran, Jenna A., Narayan, Rupa, Neuberg, Donna S., Ramos, Aura Y., Som, Tina T., Vartanian, Megan, Chen, Yi-Bin, Hobbs, Gabriela S.

“…Angiogenesis is increasingly known to play a role in pathogenesis of hematologic malignancies, including myeloid neoplasms. Regorafenib is a multikinase…”
Get full text